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Hypercholesterolemia is characterized by high plasma low density lipoprotein (LDL) cholesterol and often 
caused by genetic mutations in LDLR, APOB or PCSK9. However, a substantial proportion of 
hypercholesterolemic subjects do not have any mutations in these canonical genes, leaving the underlying 
pathobiology to be determined. In this study, we investigated whether combining plasma metabolomics 
with genetic information increases insight in the biology of hypercholesterolemia. For this proof of 
concept study, we combined plasma metabolites from 119 hypercholesterolemic females with genetic 
information on the LDL canonical genes. Using hierarchical clustering we identified four subtypes of 
hypercholesterolemia, which could be distinguished along two axes represented by triglyceride and large 
LDL particle concentration. Subjects with mutations in LDLR or APOB preferentially clustered together 
suggesting that patients with defects in the LDL receptor pathway show a distinctive metabolomics 
profile. In conclusion, we show the potential of using metabolomics to segregate hypercholesterolemic 
subjects in different clusters, which may help in targeting genetic analysis. 
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Hypercholesterolemia due to a high concentration of plasma low density lipoprotein (LDL) cholesterol has 
been shown to be a causal factor in accelerating atherosclerosis in a plethora of studies (1, 2). The liver 
plays a pivotal role in the regulation of cholesterol metabolism. It secretes cholesterol packaged in VLDL 
(very low density lipoprotein) particles that are subsequently converted into IDL (intermediate density 
lipoprotein) and LDL particles largely by the action of different lipases in the periphery (3). A key step in 
the uptake of cholesterol is the internalization of LDL via the LDL receptor (LDLR) (4). Mutations in the 
LDLR as well as mutations in genes encoding apolipoprotein B (APOB) or proprotein convertase 
subtilisin/kexin type 9 (PCSK9), are causally related with hypercholesterolemia (5). These genetic 
mutations, however, do not explain all hypercholesterolemic cases. For instance, in the UK pilot cascade 
project, 403 of 635 (63.5%) hypercholesterolemic subjects did not have mutations in LDLR, APOB, or 
PCSK9 (6). In a recent large scale study designed to evaluate the prevalence of a familial 
hypercholesterolemia (FH) mutation among individuals with severe hypercholesterolemia (7), only 24 of 
1,386 subjects with LDL cholesterol above 5 mmol/L were identified to have mutations in these three 
canonical genes. Although the prevalence of genetically defined hypercholesterolemia varies across 
studies (8), a substantial proportion of hypercholesterolemic subjects do not have mutations in LDLR, 
APOB or PCSK9. A major reason for this finding will be the presence of disease-causing mutations in 
other genes involved in cholesterol homeostasis either affecting the LDL receptor pathway or other yet to 
be defined mechanisms. Interestingly, whole exome sequencing of a cohort with FH subjects without 
mutations in LDLR, APOB and PCSK9 did not identify novel causal mutations (9). 
Recently, we analyzed a cohort of 119 young females with plasma LDL cholesterol above the 99th 
percentile for their age. In 20 hypercholesterolemic females, we identified 12 causal heterozygous 
mutations in LDLR and one causal heterozygous mutation in APOB (10). In the 99 remaining females we 
found 8 subjects carrying a variant in LDLR or APOB with unknown clinical significance (10). This left us 
with 91 females that suffered from hypercholesterolemia caused by either a polygenic (11) or epigenetic 












(12) mechanism, or presence of pathogenic variant in yet unknown genes. To get further insight in the 
underlying pathobiology of hypercholesterolemia of unknown origin, we performed plasma metabolite 
analysis on all the 119 hypercholesterolemic females. We hypothesized that mutations in genes belonging 
to the same metabolic pathway (e.g. the LDL receptor pathway) should render a similar plasma 
metabolome. This analysis differentiated four subgroups, which could be distinguished along two axes 
represented by plasma triglyceride and large LDL particle concentration. 
 
  












Materials and Methods 
Participants 
The selection of the participants (N = 119) in this study is described in detail elsewhere (10). In brief, 
these women were apparently healthy, aged 25 to 40 year and had plasma LDL cholesterol level above 4.7 
mmol/l. Exclusion criteria were diagnosis of cardiovascular disease (e.g. myocardial infarction, stroke or 
coronary surgery), diabetes mellitus, use of lipid-lowering drug, or having aberrant thyroid, liver or kidney 
function. 
Next generation sequencing 
With a custom target sequencing array developed based on the SureSelect capture system, we sequenced 
the coding regions of 11 genes, including LDLR, APOB, PCSK9, LDLRAP1, APOE, ABCG5, LIPA, 
STAP1, MTTP, ANGPTL3, and SAR1B to assess a monogenic cause of hypercholesterolemia. If a 
mutation had minor allele frequency below 0.1% in the Genome of Netherlands (13), it was considered a 
rare mutation. Mutations that are verified to cause hypercholesterolemia were listed in our previous 
publication (10). 
Detection of copy number variations (CNV) was performed using the CoNVaDING (Copy Number 
Variation Detection in Next-generation sequencing Gene panels) (14). Detected CNVs were validated 
using either multiplex ligation-dependent probe amplification, or by long-range PCR or real-time PCR 
(10). 
Genetic risk score calculation 
To study a possible polygenic cause of hypercholesterolemia, we calculated the weighted genetic risk 
score (wGRS). The Global Lipid Genetic Consortium (GLGC) meta-analysis of genome-wide association 
studies identified 95 loci affecting LDL cholesterol concentration (15). Among these loci, 12 single 
nucleotide polymorphisms (SNP) had the highest power to discriminate between FH mutation-negative 
individuals and the general population (11, 16). For each individual, we calculated the wGRS using the 












weighted sum of the risk allele (the LDL-C-raising allele) (10). The weights used were the corresponding 
per-allele effect in plasma LDL cholesterol changes reported by the GLGC (15). 
Lifestyle score calculation 
To investigate the association between lifestyle and plasma metabolome in hypercholesterolemic females, 
we used a recently described healthy lifestyle score (17). Points were given for the major lifestyle 
parameters including smoking status and eating habits. The details were described in our previous 
publication (10). In short, a maximum of 4 points reflects a very healthy lifestyle. The smaller the score is, 
the less healthy lifestyle will be. The minimum point is 0. 
Metabolite measurements 
Fasting plasma samples were routinely collected by Lifelines (www.lifelines.nl) and stored at −80∘ until 
analysis on the Nightingale metabolomics platform (Nightingale Health, Finland). This platform includes 
225 metabolic features including lipids, lipoproteins, fatty acids, amino acids, and glycolysis precursor 
molecules listed on https://nightingalehealth.com/biomarkers, using a NMR spectroscopy platform (18, 
19). 
Statistical analysis 
To explore subtypes of hypercholesterolemia, we performed hierarchical clustering based on the plasma 
metabolomics data. Since the metabolomics data contains measurements of different units, we first scaled 
the data so that every variable had mean 0 and standard deviation 1. Next, we ran the hierarchical 
clustering with the function hclust from R. We used Elucidation distance as the dissimilarity measure and 
complete linkage as the similarity measure between the clusters. The dendrogram was made by using the 
ggdendro and ggplot2 (20) R package. Finally, we cut the dendrogram into four clusters by using cutree 
function in R. 
To identify the cluster corresponding to hypercholesterolemia due to defects in the LDL receptor pathway, 
we performed principal component analysis (PCA) on the metabolomics data. Since the data contains 
measurements of different units, we converted the metabolomics data into ranks, so that every metabolite 












had value ranging between 1 and 119. We then calculated the covariance matrix and performed 
eigenvector decomposition. Entries of every eigenvector are also called loadings. Based on the loadings, 
we identified metabolites that most correlated to the first and second principal components by calculating 
the Spearman correlation coefficients. 
To evaluate associations between genetic risk/lifestyle scores and metabolite concentrations, we applied a 
nonparametric method, namely the Kendall’s tau correlation test. We reported the Kendall’s tau 
correlation coefficient and p value. A p value below 0.05 is considered significant. 
  













A group of 119 young women with hypercholesterolemia, defined as plasma LDL cholesterol levels above 
the 99th percentile for their age, was selected from the Lifelines cohort. The baseline characteristics are 
presented in Table 1. To analyze the underlying pathobiology of the hypercholesterolemic phenotype, 
plasma metabolomics was performed using the Nightingale platform. Although the absolute values 
measured in the Nightingale platform are lower than the conventional measured plasma lipids, the two 
measurements showed similar pattern (Table 1). A summary of all the results of metabolite analysis is 
presented in Supplemental Table S1. Hierarchical clustering analysis of the metabolomics data set 
revealed three main clusters and one cluster containing only one sample (Figure 1). The size of the cluster 
1, 2, 3, and 4 was 43, 15, 60 and 1, respectively. 
To analyze the divergence of the different clusters, we ran principal component analysis. The first and 
second principal component explained 38% and 21% of the total variance of the metabolic variables 
across the 119 individuals, respectively (Figure 2). To understand which metabolites correspond to the 
first and second principal component the most, we calculated the Spearman correlation coefficients 
between original variables and principal components (Supplemental Table S2). We observed that plasma 
triglyceride and large LDL particle concentration were the most correlated variables with the PC1 
(Spearman correlation coefficient -0.988) and PC2 (Spearman correlation coefficient -0.978), respectively. 
Therefore, we used these two variables to represent the axes of PC1 and PC2 (Figure 3). Our next question 
was whether the 4 clusters derived from the hierarchical clustering analysis (Figure 1) were indeed 
separated by PC1 and PC2. To answer that, we added the hierarchical clustering results to the scatterplot 
(Figure 3). Inspection reveals that the females in cluster 3 are separated from the other groups by showing 
a high plasma large LDL particle concentration coupled with relatively low plasma triglyceride, 
suggesting a defect in hepatic LDL uptake. 
Since we sequenced LDLR, APOB and PCSK9 in all subjects, we could verify whether indeed the females 
with known heterozygous mutations in the LDL receptor pathway plot in the region of cluster 3. Indeed, 












from 20 subjects with heterozygous mutations in LDLR or APOB 15 subjects were located in cluster 3 
(Figure 4). The other 5 carriers were found in cluster 1 (n = 3) and cluster 2 (n = 2). In addition, we 
identified 8 women who were heterozygous carrier of a novel variant in LDLR or APOB from which the 
pathogenicity has not yet been determined. Five of these 8 subjects were positioned in cluster 3 and three 
in cluster 1 (Figure 5). 
To improve our understanding of the underlying pathobiology of the elevated plasma LDL cholesterol in 
the remaining 91 women, we calculated the weighted genetic risk score (wGRS) and lifestyle score, and 
assessed the associations between both scores and plasma concentrations of large LDL particle and 
triglyceride. As shown in Supplemental Figure S1 and Supplemental Figure S2, no relation could be 
demonstrated between both scores and plasma large LDL particle concentration (wGRS: Kendall tau 
correlation coefficient -0.017, p value = 0.80. Lifestyle score: Kendall tau correlation coefficient -0.04, p 
value = 0.57). Both scores showed moderate association with plasma triglyceride concentration (wGRS: 
Kendall tau correlation coefficient -0.156, p value = 0.02. Lifestyle score: Kendall tau correlation 
coefficient -0.198, p value = 0.0099). 
  













In the current study, we showed that combining plasma metabolomics data with genetic information can 
improve our understanding of the origin of severe hypercholesterolemia in young healthy women. These 
analyses may help the diagnosis and personalized treatment of patients with hypercholesterolemia in 
which no causal mutations in the canonical LDL genes can be identified. 
Metabolic profiling has been used in a large number of cohort studies to assess the value of circulating 
metabolites in prediction of risk for cardiovascular events (21, 22). More specifically, metabolomics has 
been used to study associations between circulating metabolites and statin usage (23), CETP inhibition 
(24) and PCSK9 inhibition (25), generating insight in the broad metabolic effects of these interventions. 
Nightingale metabolomics data contain not only concentrations in different units, but also other quantities 
such as ratios, percentages, degrees of saturation and lipoprotein particle size. Therefore, in the current 
study, we scaled all the metabolic variables to make them have equal importance in the hierarchical 
clustering. 
The hierarchical clustering analysis revealed four clusters in the 119 hypercholesterolemic females with 
plasma LDL cholesterol above 99th percentile for their age. We hypothesized that mutations in genes 
belonging to the same metabolic pathway (e.g. the LDL receptor pathway) should render a similar plasma 
metabolome (one cluster). The principal component analysis revealed that plasma triglyceride and large 
LDL particle concentrations were the major discriminators for the four clusters. Since cluster 3 is 
characterized by a high concentration of large LDL particle and relatively low triglyceride in plasma, we 
hypothesized that this cluster represented the hypercholesterolemia due to defective LDL clearance. 
Incorporation of the genetic information provided us the verdict, because we expected the 20 subjects 
carrying a known functional heterozygous mutation in LDLR or APOB positioning in cluster 3. Indeed, 15 
subjects fit this hypothesis and were located in cluster 3. 
Then we came up with the question “Can we get insight if a novel variant in LDLR or APOB is the 
underlying cause for the severe hypercholesterolemia based on the metabolome profile?”. Indeed, 6 out of 












8 carriers of a novel mutation fit in cluster 3, suggesting potential effects of these variants on LDL 
receptor mediated uptake. This observation suggests that metabolic profiling is useful to delineate the 
subjects with a pathogenic mutation from those that do not carry any variant in either LDLR or APOB. 
However, not all subjects in cluster 3 do carry a variant in LDLR or APOB. We realize that the pathway of 
LDL receptor mediated endocytosis and intracellular cholesterol trafficking contains many more genes 
(26–28) than we have sequenced in our cohort. So expansion of the number of genes on the chip or 
choosing whole genome sequencing will ultimately improve the information on all genes involved in the 
LDL receptor pathway and may thus help to identify additional genetic variants underlying the 
pathobiology in the remaining 40 females in cluster 3. Meanwhile, we cannot exclude other processes 
underlying the hypercholesterolemia such as epigenetic changes (12), lincRNA (29), microRNA (30) or 
combinations thereof. 
Cluster 4 contained only one subject, and the individual had the highest large LDL particle concentration 
among the 119 hypercholesterolemic females. Interestingly, we did not identify any mutations in the 
sequenced genes including LDLR, APOB and PCSK9. This female subject was 28 years with BMI 21.7. 
Her waist circumference was 69 centimeters. When we compared her plasma metabolomics data to the 
other 118 hypercholesterolemic females, we identified 77 outlier variables (either below the 1st quantile 
1.5×IQR or above the 3rd quantile 1.5×IQR, IQR refers to interquantile range. Supplemental Table S3). 
We noticed that this female had a high proportion of esterified cholesterol in VLDL and HDL particles 
compared to the remaining 118 subjects. Interestingly, the CETPtg/apoCI-/- mouse model showed a very 
similar phenotype (31). Apolipoprotein C1 is an important regulator for CETP activity, which may partly 
underlie the observed phenotype (32). So far no mutations in APOC1 have been described. 
A recent study (33) showed that hypercholesterolemic subjects without any known genetic defect had 
lower levels of LDL cholesterol than those with a mutation. Therefore, we hypothesized that the origin of 
the hypercholesterolemia in cluster 1 may be either polygenic or due to lifestyle factors. Additional 
analysis of relationships between the wGRS or lifestyle score and triglyceride or large LDL particle 












concentration, we observed that only genetic risk scores were negatively associated with triglyceride 
concentration (Kendall tau correlation coefficient -0.23, p value = 0.04). This observation suggests that 
this cluster of hypercholesterolemic subjects may be caused by less damaging mutations in genes involved 
in the LDL receptor pathway. The major observation in the subjects located in cluster 2 is that they had 
elevated plasma triglyceride. The genetic array used in the current study does not contain the genes 
involved in triglyceride metabolism. Our data suggest that generation of a triglyceride specific gene array 
may generate interesting results in the subjects in this cluster. 
In summary, this study shows that bioinformatic analysis of metabolomics data derived from 
hypercholesterolemic subjects generates interesting clusters of patients that may help guiding targeted 
genomics approaches hypercholesterolemia. 
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Table 1 Characteristics of 119 hypercholesterolemic females 
 N Mean  
Standard deviation 
 
Age (year) 119 32.90 ± 4.37  
BMI 119 27.9 ± 5.10  








119 5.25 ± 0.50 2.27 ± 0.26 0.66 
Total cholesterol 
(mmol/l) 
119 7.17 ± 0.64 5.57 ± 0.43 0.68 
Triglyceride 
(mmol/l) 
119 1.50 ± 0.68 1.45 ± 0.47 0.96 
HDL cholesterol 
(mmol/l) 
119 1.39 ± 0.28 1.47 ± 0.22 0.84 
ApoB (g/l) 119 1.25 ± 0.14 1.10 ± 0.11 0.78 
 












Figures and figure legends 
	
Figure 1 Hierarchical clustering of plasma metabolomics data derived from 119 hypercholesterolemic 
females. Elucidation distance was used as the dissimilarity measure and complete linkage was used as the 
dissimilarity measure between the clusters. 
	 	













Figure 2 Proportion of variance explained by principal components derived from plasma metabolomics 
data of 119 hypercholesterolemic females. 	 	













Figure 3 Plasma triglyceride against large LDL particle concentration in 119 hypercholesterolemic 
females. Different colors refer to the hierarchical clustering outcomes (red: cluster 1, blue: cluster 2, 
green: cluster 3, purple: cluster 4). 
	 	













Figure 4 Plasma triglyceride against large LDL particle concentration in 119 hypercholesterolemic 
females. Different colors refer to the hierarchical clustering outcomes (red: cluster 1, blue: cluster 2, 
green: cluster 3, purple: cluster 4). The hypercholesterolemic females with mutations that were known to 
affect the LDL receptor pathway were highlighted. 
	 	













Figure 5 Plasma triglyceride against large LDL particle concentration in 119 hypercholesterolemic 
females. Different colors refer to the hierarchical clustering outcomes (red: cluster 1, blue: cluster 2, 
green: cluster 3, purple: cluster 4). The highlighted dots represent 8 individuals who carry a heterozygous 
variant in LDLR or APOB of unknown clinical significance. The specific variant in LDLR or APOB is 
shown. 	
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